Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03236792 | Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis | completed | Phase 1 / Phase 2 | 28 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT01886859 | Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 26, 2022 |
| clinicaltrials |
| NCT01677858 | A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma(CHAMPION 1) | completed | Phase 1 / Phase 2 | 116 | AmgenINDUSTRY | 1 | Sep 23, 2022 | clinicaltrials |
| NCT03905135 | Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies | completed | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | Sep 13, 2022 | clinicaltrials |
| NCT03036904 | Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas(V+DA-EPOCH-R) | completed | Phase 1 | 31 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT03527147 | Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)(PRISM) | completed | Phase 1 | 30 | Acerta Pharma BVINDUSTRY | 2 | Aug 15, 2022 | clinicaltrials |
| NCT03630159 | Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients(PORTIA) | completed | Phase 1 | 12 | Novartis PharmaceuticalsINDUSTRY | 3 | Aug 15, 2022 | clinicaltrials |
| NCT00784823 | Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma(Mel-Vel) | completed | Phase 1 / Phase 2 | 32 | Hackensack Meridian HealthOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT02384083 | Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients | completed | Phase 1 / Phase 2 | 47 | PETHEMA FoundationOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT03650491 | A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | completed | Phase 1 | 31 | Fortis Therapeutics, Inc.INDUSTRY | 1 | Jul 27, 2022 | clinicaltrials |
| NCT03297424 | A Study of PLX2853 in Advanced Malignancies. | completed | Phase 1 | 49 | Opna Bio LLCINDUSTRY | 1 | Jul 25, 2022 | clinicaltrials |
| NCT02049541 | Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma | completed | Phase 1 | 18 | Kami Maddocks, MDOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT02529813 | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | completed | Phase 1 | 26 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT02877550 | Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients | completed | Phase 1 | 25 | Swiss Cancer InstituteOTHER | 1 | Jun 10, 2022 | clinicaltrials |
| NCT01865617 | Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 204 | Fred Hutchinson Cancer CenterOTHER | 1 | May 25, 2022 | clinicaltrials |
| NCT02419560 | Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL | completed | Phase 1 | 37 | Craig Portell, MDOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT03682796 | Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma | completed | Phase 1 | 32 | Triphase Research and Development III Corp.INDUSTRY | 2 | May 19, 2022 | clinicaltrials |
| NCT03141203 | Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients(RomiCar) | completed | Phase 1 / Phase 2 | 50 | University of BirminghamOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT02584920 | A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma | completed | Phase 1 / Phase 2 | 87 | Shanghai Henlius BiotechINDUSTRY | 0 | May 9, 2022 | clinicaltrials |
| NCT02468687 | NMP in Relapsed / Refractory Myeloma | completed | Phase 1 | 13 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT02689453 | Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) | completed | Phase 1 | 11 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2022 | clinicaltrials |
| NCT03288480 | A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 24 | Promontory Therapeutics Inc.INDUSTRY | 1 | Apr 26, 2022 | clinicaltrials |
| NCT02514668 | A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma | completed | Phase 1 | 55 | SanofiINDUSTRY | 3 | Apr 25, 2022 | clinicaltrials |
| NCT02631577 | A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma | completed | Phase 1 / Phase 2 | 38 | Hoffmann-La RocheINDUSTRY | 2 | Apr 13, 2022 | clinicaltrials |
| NCT02471911 | KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma(KPT-330+RICE) | completed | Phase 1 | 22 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 12, 2022 | clinicaltrials |
| NCT01791595 | A Phase I Trial of AZD3965 in Patients With Advanced Cancer | completed | Phase 1 | 53 | Cancer Research UKOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT01655225 | A Study of LY3023414 in Participants With Advanced Cancer | completed | Phase 1 | 156 | Eli Lilly and CompanyINDUSTRY | 3 | Apr 8, 2022 | clinicaltrials |
| NCT01994382 | Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL | completed | Phase 1 / Phase 2 | 260 | Alexion Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 5, 2022 | clinicaltrials |
| NCT03489525 | MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma(MEDI2228) | completed | Phase 1 | 107 | MedImmune LLCINDUSTRY | 4 | Mar 28, 2022 | clinicaltrials |
| NCT04163107 | Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma(MYELOMA-HCQ) | completed | Phase 1 | 19 | Norwegian University of Science and TechnologyOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT03464916 | Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients | completed | Phase 1 | 10 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Mar 16, 2022 | clinicaltrials |
| NCT04280328 | Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 7 | Corvus Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 11, 2022 | clinicaltrials |
| NCT02293109 | Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma | completed | Phase 1 | 10 | Mehrdad Abedi, MDOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT03974243 | Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 9 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Mar 9, 2022 | clinicaltrials |
| NCT03925935 | Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation | completed | Phase 1 | 42 | Angiocrine BioscienceINDUSTRY | 1 | Mar 3, 2022 | clinicaltrials |
| NCT02514239 | Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients | completed | Phase 1 | 43 | Boehringer IngelheimINDUSTRY | 2 | Feb 24, 2022 | clinicaltrials |
| NCT01583283 | Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma | completed | Phase 1 | 38 | CelgeneINDUSTRY | 1 | Feb 23, 2022 | clinicaltrials |
| NCT04955340 | A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat | completed | Phase 1 | 5 | 4SC AGINDUSTRY | 1 | Feb 18, 2022 | clinicaltrials |
| NCT03111992 | Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma | completed | Phase 1 | 26 | Novartis PharmaceuticalsINDUSTRY | 4 | Feb 9, 2022 | clinicaltrials |
| NCT02077166 | Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | completed | Phase 1 / Phase 2 | 138 | Pharmacyclics LLC.INDUSTRY | 4 | Feb 4, 2022 | clinicaltrials |
| NCT01496118 | Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 80 | SCRI Development Innovations, LLCOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT04811898 | A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment(LNA-i-miR221) | completed | Phase 1 | 17 | Azienda Ospedaliera Universitaria Mater Domini, CatanzaroOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT00477412 | Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 107 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 28, 2022 | clinicaltrials |
| NCT00924326 | CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Jan 12, 2022 | clinicaltrials |
| NCT01962792 | Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 84 | Pharmacyclics LLC.INDUSTRY | 2 | Dec 21, 2021 | clinicaltrials |
| NCT02613598 | Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma | completed | Phase 1 | 15 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT01421186 | A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 91 | MorphoSys AGINDUSTRY | 2 | Nov 16, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Sep 29, 2022source: clinicaltrials